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Herpes simplex virus (HSV) causes a wide range of 
clinical manifestations, varying from minor cold sores to 
severe necrotizing encephalitis or disseminated systemic 
infections. The virus has the ability to establish and 
maintain a latent infection, which can be reactivated.r 
Between 80% and 90% of the European population is 
infected with HSV type I, and most infections are spread 
during the initial, subclinical phase. Fulminant HSV 
infection is very uncommon, and occurs more frequently 
in patients with impaired immunity. A review of the 
literature showed that, among 55 patients with fulminant 
HSV infection, 13 well-documented cases of fulminant 
primary HSV infection in immunocompetent patients 
have been reported, 2-6 but none of these cases involved 
reactivation of latent infection. If fulminant HSV 
infection is not diagnosed or considered in time, and 
antiviral treatment-even empirically-initiated, the 
condition of both immunocompetent and immunocom- 
promised patients will deteriorate rapidly. 
Here we describe an apparently immunocompetent 
woman with fulminant reactivation of HSV infection. 
A 64-year-old woman was admitted to our hospital 
in March 2000, complaining of sore throat, dysphagia 
and low-grade temperatures for 4 days. Her family history 
and previous medical history were unremarkable, and 
she was taking no medications. Physical examination 
at admission revealed stomatitis with oropharyngeal 
ulceration. The white blood cell (WBC) count was 
12x1012/L, with 90% neutrophils and 3% lymphocytes. 
Biochemical examination showed an elevation of C- 
reactive protein (CRP) to 150 mg/L. The patient’s 
clinical condition worsened, with continued fever peaks 
between 39°C and 40°C generalized edema due to hypo- 
albuminemia, tenderness of skeletal muscles, and livid 
erythema around small joints. Her stomatitis became 
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gangrenous (Figure l), the WBC count increased to 
35 x1012/L, the CRP level increased to 400 mg/L, and the 
liver enzymes were found to be elevated to a minor 
degree. Klebsiellapneumoniae grew in a bacterial throat 
swab, whereas cultures of urine, sputum and blood all 
gave negative results. A throat swab for detection of 
viruses was not taken. A granulating inflammation was 
found in a biopsy taken from an ulcer on the tongue. 
Virus serology (a-method without differentiation between 
HSV I and II antibody, Dade-Behring) revealed a 
positive HSV IgG titer without IgM positivity. Despite 
2 weeks of antibiotic treatment, the patient’s clinical 
condition deteriorated dramatically. 
At this time, clinical examination revealed crackles 
on both lungs, and a chest X-ray exhibited bilateral 
interstitial pulmonary opacities. Bronchoscopy with 
bronchoalveolar lavage (BAL) was performed, and 
HSV type I was found by means of an immuno- 
fluorescence assay with fluoroisothiocyanate (FITC)- 
conjugated monoclonal antibodies and confirmed by 
tissue culture on MRC-5 cells. Nasal swabs also tested 
positive for HSV type I in like manner. Because of the 
patient’s fulminant course, her clinical presentation 
with tenderness of skeletal muscles and livid erythema 
around small joints, and the strongly elevated inflam- 
mation parameters, we assumed that there was an under- 
lying autoimmune disease, e.g. vasculitis or polymyositis. 
We performed extensive diagnostic investigations, in- 
Figure 1. Patient 5 days before treatment was started. 
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eluding, among others, the determination of total 
immunoglobulins, antibodies and autoantibodies (e.g. 
HIV, ENA including Jo-l, and ANCA), blood sugar 
level, aldolase activity and cellular immune status, bone- 
marrow puncture, magnetic resonance imaging of 
head and skeletal muscles, and computed tomography 
scan of the abdomen. As the condition of the patient 
deteriorated further, we started, in parallel, treatment 
with acyclovir (7.5 mg/kg body weight every 8 h by 
intravenous infusion) and corticosteroids. This treat- 
ment regimen resulted in a rapid improvement of her 
condition, with resolution of the fever within 2 days, 
return of CRP and WBC to normal values within 7 days, 
and cessation of the progress of gangrenous stomatitis. 
However, 1 day after initiation of therapy, increasing 
tracheobronchial secretory obstruction required tracheo- 
tomy. The results of all the diagnostic tests revealed no 
pathologic findings. Consequently, steroids were discon- 
tinued. Acyclovir was continued for a total of 3 weeks, 
and the patient was transferred to the Department of 
Dental Surgery for plastic reconstruction (Figure 2). 
More than 2 years after this fulminant HSV infection, 
and several cosmetic operations, she is still in good 
condition, and the laboratory parameters are within 
normal limits. 
Fulminant HSV infection is very uncommon in the 
adult population. Fifty-five well-documented cases have 
been previously reported in the literature. Disseminated 
HSV infection occurs more frequently when an under- 
lying condition, resulting in immunosuppression, is 
present. Of the 55 cases that have been reported, 42 
(76%) had an underlying condition that was associated 
with impaired host defense. Of this group, 11 (26%) 
were patients who were receiving glucocorticoid therapy 
for various diseases such as Crohn’s disease, systemic 
lupus erythematosus, or sarcoidosis, and nine (21%) 
were receiving immunosuppressive therapy following 
transplantation. In total, eight patients had diseases 
such as acquired immunodeficiency syndrome, leukemia, 
or thymus dysfunction. Fourteen cases (33%) were 
associated with pregnancy. 1,3,7 In 13 (24%) of the 55 
cases fulminant HSV infection developed in apparently 
healthy individuals. 2-6 In some of these patients, a first 
manifestation of HSV infection was diagnosed; in 
Figure 2. Patient 1 month after treatment was started. 
others, no distinction between primary infection and 
reactivation was made. 
To our knowledge, this is the first report of fulminant 
HSV reactivation in an immunocompetent person. 
Repeated serology by ELISA revealed a positive IgG 
titer against HSV, specific IgM was not detected. This, in 
combination with HSV detection by immunofluorescence 
and tissue culture, is strong evidence for reactivated 
HSV infection. The kinds of opacity in the chest X-ray 
film being consistent with viral pneumonia, as well as the 
positive immunofluorescence assay, the positive tissue 
culture for HSV in the BAL, and the improvement 
after treatment with acyclovir, are all indicative of a 
disseminated HSV infection rather than a contamina- 
tion of the BAL from the pharynx. Because of the 
fulminant course and our initial assumption of an 
underlying autoimmune disease, we started acyclovir 
and corticosteroids in parallel. The extensive diagnostic 
investigation for an impaired host defense, including 
cellular immune status, was negative, and the patient’s 
condition improved even after discontinuation of 
steroids. Considering the negative medical history, 
and especially the normal findings in the follow-up of 
more than 2 years, we assume that our patient is immuno- 
competent. 
Without antiviral treatment, the mortality rate of 
disseminated HSV infection is very high, emphasizing 
the fulminant and lethal nature of this disease.The overall 
mortality of the 55 cases with fulminant HSV infection 
was 69%. Ten (77%) of the 13 apparently immuno- 
competent patients with fulminant HSV infection 
died. The three surviving patients were all treated with 
acyclovir.2-6 Only three of the 10 patients who died 
received antiviral treatment, i.e. acyclovir or vidarabine. 
Independent of the immune status, early antiviral 
treatment has to be regarded as decisive for patients’ 
outcome. In about half of patients, the ‘typical’ herpetic 
mucocutaneous lesions do not occur before HSV 
dissemination. Therefore, in these patients early diag- 
nosis is difficult to achieve.2 Fulminant HSV infection 
should be considered in the differential diagnosis of any 
patient with a clinical picture of systemic infection. 
Confirmation of the diagnosis requires the detection of 
viral antigen in nasal or throat swabs or in BAL by IFA, 
followed by tissue culture. The detection of HSV-specific 
IgM and/or a significant increase in titer of HSV-specific 
IgG is certainly not sufficient to detect a reactivation 
of HSV type I or II, because: (1) in many cases HSV- 
specific IgM cannot be found; and (2) in most cases, an 
increase of specific IgG can be observed about 2 weeks 
after onset of illness. If a disseminated HSV infection is 
considered, empirical antiviral therapy should be 
initiated even in cases of pending definitive diagnosis. 
Early treatment definitely results in an improvement of 
prognosis, and acyclovir represents the therapy of first 
choice. As an alternative, foscarnet or cidofovir can be 
used for systemic infection.8 
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